(1888PressRelease)
November 11, 2008 - VANCOUVER, CANADA – In this month of international Lung Cancer Awareness, Perceptronix Medical Inc. (Perceptronix) is pleased to announce the initiation of a new, longitudinal study with the Respiratory Department of Saint Paul’s Hospital (Vancouver, Canada). Dr. Pearce Wilcox, MD, FRCP and his team will evaluate the use of LungSign™ in monitoring for recurrence in subjects with recently re-sected lung cancer. Recurrence rate for lung cancer after resection can be in range from 5% to 15% thus early detection of recurrence among these patients could save many lives.
LungSign™ is a safe, virtually painless and convenient test to assess a patient’s risk of lung cancer based on an innovative marker in sputum that is highly correlated with the presence of lung malignancy – even in early stage, presymptomatic disease. LungSign™ is the first test in the market that provides both an independent result to help with early detection of lung cancer and a useful complement to current radiological diagnostic methods.
About Perceptronix Medical Inc.
Perceptronix Medical Inc (“Perceptronix” or the “Company”) is a privately owned, independent cytology laboratory and cancer diagnostics company specializing in the provision of innovative early cancer detection tests based on quantitative cytology. The Company’s DNA image cytometry technology was developed in partnership with the British Columbia Cancer Agency (BCCA) in Vancouver. Quantitative cytology provides physicians with an improved cytopathology assessment based on an objective measure of large-scale DNA abnormality that can indicate precancerous or cancerous changes. In addition to general quantitative cytology services, the company has developed innovative tests for the early detection of lung cancer and oral cancer.
###
